Premium Nahrungsergänzungsmittel | artgerecht

Anticoagulation – Blood Clot Prevention Explained

Anticoagulation refers to the use of medications that inhibit blood clotting to prevent and treat thrombosis and embolism.

Regular tips about health Regular tips about health

Things worth knowing about "Anticoagulation"

Anticoagulation refers to the use of medications that inhibit blood clotting to prevent and treat thrombosis and embolism.

What is Anticoagulation?

Anticoagulation is the therapeutic use of medications that inhibit or slow down the process of blood clotting (coagulation). The goal is to prevent the formation of blood clots (thrombi) or to stop existing clots from growing. Anticoagulation is a fundamental principle in modern medicine and is used across a wide range of medical conditions.

When is Anticoagulation Used?

Anticoagulant medications are prescribed in various medical conditions where there is an increased risk of thrombosis or embolism:

Atrial fibrillation: To prevent strokes caused by clots forming in the heart
Deep vein thrombosis (DVT): Treatment and prevention of blood clots in the deep veins
Pulmonary embolism: Treatment of a blood clot in the pulmonary vessels
Mechanical heart valves: Prevention of thromboembolic events in patients with artificial heart valves
Post-surgical care: Short-term thrombosis prevention after major surgery or prolonged immobility
Antiphospholipid syndrome: Management of an autoimmune condition that increases clotting risk

Mechanism of Action

Blood coagulation is a complex cascade involving numerous clotting factors. Anticoagulants interfere with this process at different points:

Vitamin K Antagonists

Agents such as warfarin or phenprocoumon inhibit the liver synthesis of vitamin K-dependent clotting factors (II, VII, IX, and X). Their effect is delayed and must be regularly monitored using the INR value (International Normalized Ratio).

Heparins

Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) such as enoxaparin or dalteparin enhance the activity of antithrombin, a natural inhibitor of coagulation, thereby blocking clotting factors Xa and IIa (thrombin).

Direct Oral Anticoagulants (DOACs)

The newer class of direct oral anticoagulants (also called NOACs) targets specific clotting factors directly:

Factor Xa inhibitors: Rivaroxaban, apixaban, edoxaban
Direct thrombin inhibitors: Dabigatran

DOACs offer the advantage of easier administration and generally do not require routine laboratory monitoring.

Dosage and Monitoring

The dosage of anticoagulants is individualized and depends on the underlying condition, body weight, kidney function, and other factors. Patients on vitamin K antagonists require regular INR monitoring to maintain the therapeutic range (usually INR 2.0–3.0). Heparin therapy can be monitored via the aPTT (activated partial thromboplastin time) or anti-Xa levels. DOACs do not typically require routine coagulation monitoring but can be measured in specific clinical situations.

Side Effects and Risks

The most significant risk of anticoagulation is an increased tendency to bleed. Possible complications include:

Bruising and hematomas following minor injuries
Prolonged bleeding from wounds
Gastrointestinal bleeding
Intracranial bleeding (brain hemorrhage) as a rare but serious complication

Patients on anticoagulation should always inform their physician and all other healthcare providers about their therapy, especially before surgeries, dental procedures, or when starting new medications.

Contraindications

Anticoagulants should not be used, or used only with a careful risk-benefit assessment, in the following situations:

Active, uncontrolled bleeding
Severe renal insufficiency (depending on the agent)
Certain liver diseases
Pregnancy (special caution required; choice of agent must be considered carefully)

References

Steffel J et al. - The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal, 2018.
Hirsh J, Bauer KA, Donati MB et al. - Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008.
Lip GYH, Collet JP, Haude M et al. - 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous cardiovascular interventions. EuroIntervention, 2019.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.